ID   KBM-3/AMSA
AC   CVCL_IP19
DR   cancercelllines; CVCL_IP19
DR   Wikidata; Q54899583
RX   PubMed=1311390;
CC   Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11989; TOP2A; Simple; p.Arg487Lys (c.1460G>A); ClinVar=VCV000016772; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=1311390).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A425 ! KBM-3
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 12
//
RX   PubMed=1311390; DOI=10.1016/0022-2836(92)90245-F;
RA   Lee M.-S., Wang J.C., Beran M.;
RT   "Two independent amsacrine-resistant human myeloid leukemia cell lines
RT   share an identical point mutation in the 170 kDa form of human
RT   topoisomerase II.";
RL   J. Mol. Biol. 223:837-843(1992).
//